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The core enhancer is essential for proper timing of MyoD activation in
limb buds and branchial arches
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Transgenic analyses have defined two transcriptional enhancers that regulate MyoD expression in mammals, the core enhancer and distal
regulatory region; these enhancers exhibit complementary activities and together are sufficient to recapitulateMyoD expression in developing
and mature skeletal muscle. The core enhancer is activated in presumptive muscle cells and determined myoblasts, suggesting an important
role in initiating MyoD expression. Here, targeted mutagenesis in the mouse is used to identify necessary and redundant core enhancer
functions. The core enhancer is essential for the timely initiation of MyoD expression in limb buds and branchial arches, as enhancer deletion
delayed MyoD activation by 1 to 2 days in these muscle lineages. Functionally, this delay in MyoD transcription delayed the onset of muscle
differentiation, as assayed by expression of the gene encoding for the early differentiation marker, Myogenin. In addition to these lineage-
specific defects, a generalized, modest reduction in MyoD expression was observed in all muscle lineages and at all embryonic stages
examined. Interestingly, however, a specific defect was not observed in the nascent myocytes at the medial and lateral aspects of the
myotome, suggesting the existence of at least one other enhancer with this specificity. The core enhancer was also dispensable for Myf-5- and
Pax-3-dependent regulation of MyoD transcription. These data demonstrate a differential requirement for core enhancer activity in muscle
lineages derived from migratory precursors and suggest redundancy in cis regulatory mechanisms controlling myotomal MyoD expression.
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Introduction Myf-5. It remains controversial, however, whether theseIn vertebrate embryos, early skeletal muscle development
is controlled by signaling and transcriptional pathways that
activate expression of the muscle regulatory genes, MyoD
and Myf-5. These genes encode structurally related bHLH
transcription factors that function in a partially redundant
manner to establish myoblast identity (Kablar et al., 1999;
Rudnicki et al., 1993; Tajbakhsh et al., 1996; Wang and
Jaenisch, 1997). In the somite, where specification of trunk
myoblasts occurs (Ordahl and Le Douarin, 1992), both
positive and negative signals have been identified that
pattern the somite and regulate expression of MyoD and0012-1606/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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BMPs, regulate myogenic gene expression directly, or
function indirectly by regulating proliferation, survival or
migration (reviewed by Borycki and Emerson, 2000; Taj-
bakhsh and Buckingham, 2000; see Gustafsson et al., 2002).
The cis transcriptional circuitry controlling MyoD and
Myf-5 expression is apparently complex, as evidenced by
the number of transcription factors shown to regulate their
expression in gain- and loss-of-function experiments (Kume
et al., 2001; Heanue et al., 1999; Laclef et al., 2003; Lu et
al., 2002; Maroto et al., 1997; Ridgeway and Skerjanc,
2001; Tajbakhsh et al., 1997; Wilson-Rawls et al., 1999;
Woloshin et al., 1995) and by the identification of multiple
MyoD and Myf-5 enhancers that dictate distinct aspects of
their spatiotemporal patterns of expression (reviewed by
Pownall et al., 2002). We previously demonstrated (Chen et
al., 2001) that a 24-kb fragment of genomic sequence
upstream of the human MyoD gene is sufficient to recapit-
Fig. 1. (A) Targeting strategy for the mouse core enhancer (CE). The 258-bp core enhancer was replaced by a floxed PGKneo cassette. Homologous sequences
in the targeting vector (pDCEneotk) are delineated at the 5Vand 3Vends by XbaI and HindIII sites, respectively. The structures of the locus following
homologous recombination (CEneo) and Cre-mediated excision of the neo cassette (CEloxP) are shown. Diagnostic bands generated using the 3Vprobe on XbaI-
digested DNA are indicated above the locus diagrams. A 5Vprobe was also used to verify the integrity of the locus following homologous recombination. (B)
Representative Southern blot using the 3Vprobe on XbaI-digested DNA isolated from ES cells following electroporation with pDCEneotk. A targeted clone is
shown in lane 4. (C) Representative PCR analysis performed on tail DNA isolated from a CEloxP litter using primers flanking the 258-bp core enhancer
sequence. All genotypic classes were generated at expected Mendelian ratios. Triangles flanking PGKneo cassette represent loxP sites. Vector sequences are
denoted by a dashed line. Restriction enzymes are abbreviated as follows: B, BamHI; H, HindIII; N, NotI; P, PstI; S, SphI; X, XbaI.
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combining the complementary activities of two enhancers,
the core enhancer at 20 kb (Goldhamer et al., 1992, 1995)
and the distal regulatory region at 5 kb (DRR; Asakura et
al., 1995; Tapscott et al., 1992). In the somite, the core
enhancer is activated in myogenic precursors in the dermo-
myotomal lips, in cells immediately subjacent to the der-
momyotomal lips that likely represent undifferentiated sub-
lip domain cells described in birds (Cinnamon et al., 2001),
and in nascent myocytes of the epaxial and hypaxial
myotome (Chen et al., 2001; Goldhamer et al., 1992,
1995; Kablar et al., 1998, 1999). In contrast, the core
enhancer is essentially inactive in the central epaxial myo-
tome, also known as the intercalated myotome (Sporle et al.,
2001), which expresses muscle differentiation markers such
as Myogenin (Sassoon et al., 1989; Sporle et al., 2001),
Frizzled9 (Wang et al., 1999), Myosin Light Chain 1a
(Lyons et al., 1990) and Connexin 40 (Dahl et al., 1995).
In branchial arches and limb buds, core enhancer activity is
first observed in myogenic cells before differentiation (see
Faerman et al., 1995; Kablar et al., 1998, 1999). DRR
activity, in contrast, is restricted to differentiated muscle
cells of the developing embryo; consequently, DRR trans-
genes are expressed in the intercalated myotome with the
same timing as the endogenous MyoD gene, but are signif-
icantly delayed in limb buds and facial muscles (Asakura et
al., 1995; Kablar et al., 1997). In adult musculature, theDRR is necessary for normal MyoD expression (Chen et al.,
2002), and sufficient for driving transgene expression (Asa-
kura et al., 1995; Hughes et al., 1993). In contrast, core
enhancer transgenes are not active in adult musculature
(Faerman et al., 1995). These data, together with the finding
that core enhancer transgenes are activated in presumptive
muscle progenitors of Myf-5; MyoD double-mutant embry-
os, which lack determined myoblasts (Kablar et al., 1999),
support the hypothesis that the core enhancer primarily
functions early in myogenesis to regulate MyoD transcrip-
tion in uncommitted myogenic precursor cells and myo-
blasts, whereas the DRR functions to maintain MyoD
expression in differentiated cells (Chen et al., 2001).
We previously identified all sequences required for core
enhancer activity in the embryo using linker-scanner muta-
genesis (Kucharczuk et al., 1999). Whereas most deleterious
mutations affected enhancer activity equivalently in all
skeletal muscle lineages, two adjacent mutations, linker-
scanner 14 and 15, defined an enhancer region required
specifically in myotomally derived musculature, where
correct activation of MyoD is Myf-5-dependent (Kablar et
al., 1997; Tajbakhsh et al., 1997). That both linker-scanner
mutations destroyed a conserved E-box having high affinity
for myogenic bHLH factors (see Blackwell and Weintraub,
1990; Wright et al., 1989) raised the possibility that Myf-5
regulates MyoD directly in myotomal muscles. Interestingly,
this enhancer region was dispensable for transgene expres-
Fig. 2. Representative northern blot showing decreased levels of MyoD
mRNA at embryonic, fetal and neonatal stages of CEloxP/loxP mutant mice.
Total RNA was isolated from wild-type and CEloxP/loxP E11.5 embryos,
decapitated E15.5 fetuses, and pooled fore- and hindlimb muscles from 7-
day-old neonates, and hybridized with MyoD- and GAPDH-specific, 32P-
labeled probes. MyoD hybridization signals were quantified and normalized
to GAPDH levels using a Storm Scanner 860 and ImageQuant software.
The estimated decrease (see text) in MyoD levels at these stages is based on
at least three independent experiments.
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and other myogenic populations derived from migratory
precursors that originate in the lateral dermomyotome,
demonstrating that distinct cis mechanisms regulate MyoD
induction in myotomal and migratory muscle lineages
(Kucharczuk et al., 1999).
Although transgenic studies have provided considerable
insight into MyoD and Myf-5 transcriptional control mech-
anisms, standard transgenesis cannot distinguish between
essential and redundant enhancer functions because regula-
tory sequences are assayed outside of their normal chromo-
somal context. In this report, we use targeted mutagenesis in
the mouse to define essential functions of the MyoD core
enhancer, to better understand the cis regulatory networks
controlling MyoD expression. MyoD activation was delayed
by 1–2 days in branchial arches and limb buds of core
enhancer mutant embryos. This perturbation in MyoD
expression delayed muscle differentiation in these lineages,
as assayed by Myogenin expression. Interestingly, however,
the core enhancer is not required for correct activation of
myotomal MyoD expression, and is not essential for either
Myf-5 or Pax-3-dependent regulation, indicating redundan-
cy in cis regulatory mechanisms controlling myotomal
MyoD expression.Materials and methods
Targeted deletion of the mouse core enhancer and
generation of chimeric mice
129/SvJ mouse genomic DNA surrounding the core
enhancer was isolated by screening a Egt11 library (Clon-
tech) by standard methods, cloned into pBluescript II KS+
(Stratagene), and restriction mapped. A 258-bp fragment
(22,462 to 22,205 relative to the MyoD transcriptional
start site; GenBank accession number, AC020786) corres-
ponding to the human core enhancer (Goldhamer et al.,
1995) was targeted for deletion by homologous recombina-
tion (Fig. 1). A 1-kb XbaI–SphI genomic DNA fragment
containing the core enhancer was subcloned into pBluescript
II KS+ (Stratagene), and EcoRI and BamHI restriction
enzyme sites were introduced at the 5Vand 3Vends of the
core enhancer sequence, respectively, by PCR (Ho et al.,
1989) using Vent polymerase. The final PCR product was
subcloned and sequenced to ensure the absence of polymer-
ization errors. Flanking homology arms of 3.3 and 3.2 kb
were subcloned 5Vand 3V, respectively, to the modified 1-kb
XbaI–SphI fragment. The 258-bp core enhancer sequence
was excised by EcoRI and BamHI restriction enzyme
digests, and replaced with a PGKneo cassette flanked by
loxP sites (from ploxPneo-1, provided by Dr. Marisa Barto-
lomei), cloned in a 3Vto 5Vorientation. AnHSVtk cassette was
cloned adjacent to the 3V homology arm. GS1 ES cells
(Genome Systems) were electroporated with 40 Ag of
NotI-linearized targeting vector and propagated as previous-ly described (Chen et al., 2002). Resistant ES colonies were
expanded and targeted clones identified by Southern analysis
of XbaI-digested DNA with a radioactive probe to a 1.2-kb
BamHI–PstI fragment 3Vto the region of homology (see Fig.
1). Targeting was confirmed by Southern analysis of SphI-
digested DNA with a 1.3-kb NotI–SphI 5Vprobe (data not
shown). To remove the neo cassette, targeted ES cell clones
were transiently transfected with the Cre recombinase ex-
pression plasmid pBS185 (Sauer and Henderson, 1990;
provided by Dr. Brian Sauer) as previously described (Chen
et al., 2002). Individual colonies were expanded and screened
by Southern analysis and PCR [using primer pairs 258.5Va.for
(5VCTT GGA ACC ACA CTA CCT CAA GG 3V) and
258.3Vb.rev (5VGTT CCT CTC ATG CCT GGT GTT TAG
G 3V)] to ensure Cre-mediated elimination of the PGKneo
cassette. Absence of the Cre plasmid was verified by PCR.
Targeted ES clones, either with (CEneo) or without
(CEloxP) the neo cassette, were injected into C57Bl/6J
blastocysts using standard techniques by the University of
Pennsylvania Transgenic and Chimeric Mouse Facility.
Chimeric mice were crossed to C57Bl/6J mice and germline
transmission was assessed by Southern analysis and PCR of
tail DNA.
Transgenic mice
Production of transgenic mice, generation of embryos for
analysis and whole-mount staining for h-gal activity were
done as previously described (Chen et al., 2001; Kucharc-
zuk et al., 1999).
Mouse breeding and embryo genotyping
Mutant lines were maintained by interbreeding to C57Bl/
6J mice, resulting in a mixed B6, 129 background. For in
situ and northern analyses, heterozygous core enhancer
mutant mice were mated and litters harvested at various
stages with noon of the day of plug considered E0.5. Somite
Fig. 3. Whole-mount in situ hybridization for MyoD mRNA in wild-type (A–D) and CEloxP/loxP (E–H) littermates from E9.75 to E12.5. MyoD expression in
the branchial arches was not detected at E9.75 in core enhancer-mutant embryos (A, E; insets are higher magnifications of the first branchial arch) and remained
dramatically lower than wild type in developing facial musculature at E10.5 (B, F; red arrows, branchial arch and extraocular muscle precursors). The onset of
MyoD expression in the limb buds was also delayed in mutant embryos (B, F). By E11.5 (C, G), MyoD expression in musculature of the face and limbs had
largely recovered although overall levels remained lower in mutants (compare hindlimb buds, arrows). A small reduction in MyoD expression in somites was
observed in mutant embryos (A–C, E–G), although the timing of expression was not altered (A, E). At E12.5 (D, H), levels of MyoD expression were not
discernibly different in wild-type and mutant embryos.
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embryos, according to Rugh (1991). To obtain CEloxP; Myf-
5 double-mutant embryos, CEloxP/loxP mice were interbred
with Myf-5+/ mice (Braun et al., 1992) to generate CE+/
loxP; Myf-5+/ mice, which were subsequently crossed to
CEloxP/loxP mice to generate CEloxP/loxP; Myf-5+/ mice.
Embryos used for analysis were generated by intercrossing
CE+/loxP; Myf-5+/ mice, or by crossing CE+/loxP; Myf-5+/
and CEloxP/loxP; Myf-5+/ mice.
DNA was isolated from yolk sacs and genotyping per-
formed by PCR. Myf-5 genotyping was done using the
following PCR primer sequences, kindly provided by Dr.
Michael Rudnicki. The wild-type allele was detected using
Myf-5.for (5VTGA AGG ATG GAC ATG ACG GAC 3V)
and Myf-5.rev (5VTGA CCT TCT TCA GGC GTC TAC G
3V); the mutant allele was detected using Myf-5neo.for (5V
ACT GGG CAC AAC AGA CAA TCG 3V) and Myf-
5neo.rev (5VGCT TCA GTG ACA ACG TCG AGC 3V).
Whole-mount in situ hybridization
In situ hybridization with a digoxigenin-labeled MyoD
RNA probe was performed on E9.75–E12.5 mouse embry-os as previously described (Chen et al., 2001, 2002). In situ
hybridization for Myogenin was performed with an anti-
sense RNA probe corresponding to nucleotides 791–1486
of the Myogenin cDNA (Sassoon et al., 1989).
RNA isolation and northern analysis
Tissues were quick-frozen in liquid nitrogen and total
RNA was isolated and analyzed as previously described
(Chen et al., 2002). Probes used included full-length
mouse MyoD cDNA and an 800-bp EcoRI fragment from
the rat GAPDH cDNA. MyoD hybridization signals were
quantified using ImageQuant software (Molecular Dynam-
ics) and normalized to GAPDH. MyoD levels were quan-
tified in at least three independent experiments at each
time point.
Photomicroscopy
Embryo whole-mount images were photographed using a
Hamamatsu C5810 color video camera and Nikon SMZU
stereomicroscope under dark-field illumination. Identical
light and camera conditions were used to capture images
J.C.J. Chen, D.J. Goldhamer / Developmental Biology 265 (2004) 502–512506of littermate embryos processed side by side for in situ
hybridization. Images were captured and assembled using
Adobe Photoshop and Illustrator, respectively.Fig. 4. Whole-mount in situ hybridization for Myogenin mRNA in wild-
type (A, C, E) and CEloxP/loxP (B, D, F) E11.5 embryos. Myogenin
expression was significantly reduced in the limb buds (A, B, E, F) and
branchial arches (A–D) of mutant embryos, indicating a delay in early
myogenic differentiation in these MyoD-dependent lineages. Wild-type and
CEloxP/loxP embryos expressed comparable levels of Myogenin in the
myotomes (A, B), where muscle differentiation is MyoD-independent.Results
Generation of core enhancer mutant ES cells and chimeric
mice
To define essential functions of the MyoD core enhancer,
the sequence corresponding to the 258-bp core region of the
human fragment 3 regulatory region (Goldhamer et al.,
1995) was deleted in mice. The mouse and human core
enhancer share 89% identity overall (94% in the first 160
bp), with identity dropping dramatically outside of the core
enhancer, although small regions of sequence similarity
exist throughout fragment 3 (Goldhamer et al., 1995;
unpublished data). A standard replacement strategy was
used whereby a PGKneo positive selection cassette, flanked
by loxP sites, was inserted in place of the core enhancer
(Fig. 1). Cre-mediated recombination (Sauer and Hender-
son, 1988) was used to eliminate the neo cassette, leaving a
single transcriptionally inert loxP site (Arango et al., 1999)
in place of the core enhancer sequence.
Chimeric mice were generated from core enhancer-tar-
geted ES cells and germline transmission was achieved for
both CEneo and CEloxP mutations. Crosses of heterozygous
mice generated viable and fertile CEneo/neo and CEloxP/loxP
homozygous null offspring at expected Mendelian ratios
(data not shown). Replacing the core enhancer at 20 kb
with the neo cassette resulted in a generalized decrease in
MyoD expression in all myogenic lineages, reducing MyoD
mRNA levels to less than 20% of wild type at embryonic
through adult stages (data not shown).
Generalized and lineage-specific defects in MyoD
expression in CEloxP/loxP mice
MyoD expression was analyzed by northern analysis of
RNA isolated from CEloxP/loxP mutants at embryonic, fetal
and neonatal stages. At E11.5, CEloxP/loxP embryos
expressed approximately 30% less MyoD mRNA than
wild-type littermates (Fig. 2). A similar defect was observed
in E15.5 fetuses, as well as in pooled limb muscles of 7-day-
old pups, indicating a general requirement for the core
enhancer to achieve normal levels of MyoD mRNA in
embryos and neonates.
An overall decrease in MyoD mRNA levels could result
from a generalized reduction in all muscle lineages, a more
pronounced lineage specific reduction, or both. Possible
spatiotemporal defects were investigated by whole-mount
in situ hybridization of embryos from E9.75 through E12.5
(Fig. 3). In wild-type embryos, MyoD expression is first
detected in interlimb somites at E9.5–E9.75, where it is
initiated in a cranio-caudal fashion, with slightly laterdetection of transcripts in occipito-cervical somites (Chen
et al., 2001; Tajbakhsh et al., 1997). Deletion of the core
enhancer did not alter the timing or pattern of MyoD
expression in somites. At E9.75, CEloxP/loxP and wild-type
embryos exhibited staining in a comparable number of
interlimb somites, and both showed weak staining in the
somites anterior to the forelimb bud (Figs. 3A and E). At
E10.5 and E11.5, MyoD expression in somites of CEloxP/loxP
embryos continued to resemble wild-type patterning (Figs.
3B, C, F and G). Interestingly, no specific defect in MyoD
expression was observed in muscle precursors subjacent to
the dermomyotomal lips or in young myocytes of the
epaxial and hypaxial myotome at E10.5 and E11.5, although
no other MyoD enhancers are known that can direct expres-
sion in these somite subdomains. Whereas the timing and
pattern ofMyoD expression was not disrupted, we did note a
modest reduction in staining intensity throughout the myo-
tome from E9.75 through E11.5, indicating that the core
enhancer is required to achieve wild-type levels of MyoD
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intercalated myotome, a subdomain in which the core
enhancer is not sufficient to direct transgene expression
(Fig. 5A; Faerman et al., 1995; Goldhamer et al., 1992,
1995; Kablar et al., 1998, 1999). MyoD expression in
myotomal muscle populations was comparable to wild type
by E12.5 (Figs. 3D and H).
Core enhancer mutant embryos exhibited a pronounced
defect in MyoD activation in the branchial arches and limb
buds. In wild-type embryos, MyoD transcripts are first
detected by in situ hybridization at approximately E9.75
and E10.5 in branchial arches and limb buds, respectively
(Borycki et al., 1999; Chen et al., 2001, 2002). MyoD
expression was essentially eliminated in the mandibular
arch of CEloxP/loxP embryos at E9.75 (Figs. 3A and E) and
was barely detectable at E10.5 (Figs. 3B and F); over-
staining eventually revealed traces of MyoD transcripts
(data not shown). A pronounced decrease in staining was
also observed in muscle precursors of the forelimb buds at
E10.5 (Figs. 3B and F). By E11.5 (Figs. 3C and G),
expression had largely recovered in both the branchial
arches and forelimb buds, while staining intensity in the
hindlimb buds remained significantly lower than wild type.
These observations demonstrate that the core enhancer is
essential for the early activation of MyoD expression in the
major muscle lineages derived from migratory muscle
precursors. Core enhancer-independent MyoD expression
was temporally correlated with the onset of muscle differ-
entiation, approximately when DRR activity is first detected
(Asakura et al., 1995; Kablar et al., 1997).
Muscle differentiation is delayed in limb buds and branchial
arches of core enhancer mutant embryos
In MyoD knockout embryos, muscle differentiation is
delayed by approximately 2.5 days in the limb buds and
branchial arches (Kablar et al., 1997). To test whether the
delay in MyoD initiation observed in core enhancer-null
embryos affected muscle differentiation, embryos were
processed for in situ hybridization to the early differentia-
tion marker, Myogenin (Sassoon et al., 1989; Wright et al.,
1989). As expected, Myogenin expression in the myotomes
was comparable to that of wild-type littermates at E10.5
(data not shown) and E11.5 (Figs. 4A and B), consistent
with the dispensability of MyoD for myotomal myogenesis
(Kablar et al., 1997; Ordahl and Williams, 1998). In wild-
type embryos, Myogenin transcripts are first detected by in
situ hybridization at E10.5 and E11.5 in the branchial arches
and limb buds, respectively (Asakura and Tapscott, 1998;
Faerman and Shani, 1993). Comparison of stage-matched
wild-type and core enhancer littermates revealed a consis-
tent decrease in Myogenin levels and the number of cells
expressing Myogenin in the branchial arches and limb buds
of mutant embryos at E11.5 (Figs. 4C, D, E and F), despite
the recovery of MyoD levels by this stage. This delay is
transient, as Myogenin expression in CEloxP/loxP embryoswas indistinguishable from wild-type littermates at E12.5
(data not shown).
The core enhancer is not required for Myf-5- and
Pax-3-dependent MyoD expression
MyoD expression in myotomal muscles is delayed ap-
proximately 2 days in Myf-5 mutant embryos. Recovery of
MyoD expression, which is dependent on Pax-3 (Tajbakhsh
et al., 1997), is first apparent by E11.5 and is complete by
E12.5 (Chen et al., 2002; Tajbakhsh et al., 1997). Core
enhancer transgenes exhibit a similar delay and kinetics of
recovery in Myf-5 mutants (Figs. 5A, B, E and F; see Kablar
et al., 1999), demonstrating a dependence on Myf-5 and
responsiveness to Pax-3. Adjacent linker-scanner mutations
that destroy a potential Myf-5 binding site in the core
enhancer effectively eliminate transgene expression in myo-
tomes and their derivatives (Figs. 5C and F: Kucharczuk et
al., 1999). Interestingly, these linker-scanner mutations also
render the core enhancer unresponsive to Pax-3 in myo-
tomes of Myf-5 mutant embryos (Figs. 5D and H). In
contrast to these transgenic data, targeted deletion of the
core enhancer did not delay the onset ofMyoD expression in
myotomal muscles (Figs. 3A, B, E and F), demonstrating
that the core enhancer is dispensable for Myf-5-dependent
MyoD activation. To determine whether the core enhancer is
required for Pax-3-dependent expression of MyoD, embryos
mutant for both Myf-5 and the core enhancer were analyzed
by in situ hybridization. As expected, MyoD expression in
the myotomes was delayed in CE+/loxP; Myf-5/ and
CEloxP/loxP; Myf-5/ embryos at E10.5 (data not shown).
Deletion of the core enhancer, however, did not affect the
timing or the extent of Pax-3-mediated recovery of MyoD
expression in the myotomes of Myf-5-null embryos (Fig. 6).
We conclude that the core enhancer is sufficient but not
required for Pax-3-dependent MyoD expression.Discussion
Given the role of MyoD in early myogenic specification
(Kablar et al., 1997; Rudnicki et al., 1993), we have sought
to identify the essential regulatory functions of the core
enhancer, which is a likely target of upstream signaling and
transcriptional events that regulate MyoD induction and
early myogenesis (Goldhamer et al., 1995; Kablar et al.,
1998, 1999). Deletion of the core enhancer resulted only in
loss-of-expression phenotypes, supporting previous indica-
tions that MyoD is under positive transcriptional control in
the embryo (Kucharczuk et al., 1999). As with the DRR
(Chen et al., 2002), both essential and redundant core
enhancer activities were identified. Whether the dispens-
ability of a particular enhancer activity results from the
existence of multiple, redundant enhancers that function
similarly through the use of shared transcription factor
binding sites, or from the existence of parallel, redundant
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target sequences remain to be determined. In this regard,
core enhancer and DRR knockout mice will be useful to
investigate the complex signaling and transcriptional net-
works regulating MyoD expression in the embryo.
The core enhancer is essential for the timely activation of
MyoD expression in limb buds and branchial arches
The most significant defect observed in core enhancer
mutant embryos was a marked delay in MyoD expression in
muscle precursors of the branchial arches and limb buds,
demonstrating that the core enhancer is necessary for the
timely initiation of MyoD expression in these muscle
lineages. The core enhancer became dispensable close to
the onset of muscle differentiation, consistent with a primary
function in the early activation of MyoD (Chen et al., 2001;
Faerman et al., 1995; Goldhamer et al., 1995; Kablar et al.,
1999). These data support and extend previous reporter gene
studies of the human core enhancer in transgenic mice
(Kucharczuk et al., 1999), establishing a commonality
between MyoD transcriptional control in migratory myo-
genic precursors of the head and limb. Analysis of other
muscles derived from migratory precursors, such as the
diaphragm, as well as nonmigratory head muscles (Moo-
toosamy and Dietrich, 2002; Noden, 1983), will establish
whether dependence on core enhancer activity is specific to
all migratory precursor populations.
Although little is known of the signals and transcriptional
pathways that regulate myogenesis in the head, development
of facial musculature shows unique features not shared by
trunk or limb myogenesis. For example, distinct enhancers
are utilized to regulate Myf-5 expression in the head, trunk
and limbs (reviewed by Pownall et al., 2002). In addition,
muscle development in the trunk is abrogated in embryos
mutant for both Myf-5 and Pax-3, owing to a failure to
activate MyoD and execute the myogenic program, whereas
myogenesis in the head is unaffected (Tajbakhsh and Buck-
ingham, 2000; Tajbakhsh et al., 1997). Finally, embryos
with mutations in both MyoR and capsulin, which encode
bHLH proteins and are expressed in branchial arch muscle
precursors, specifically lack muscles of mastication and fail
to activate MyoD and Myf-5 in precursors of this subset of
facial muscles, suggesting a role in early muscle specifica-
tion (Lu et al., 2002). Although MyoR (but not capsulin) is
also expressed in precursors of trunk muscles (Lu et al.,
1999; Robb et al., 1998a,b), a trunk muscle phenotype was
not observed in MyoR;capsulin double-mutant embryos (Lu
et al., 2002), probably reflecting lineage-specific MyoR
functions or differences in expression of related, compen-
satory factors. Understanding how core enhancer activity is
regulated in the branchial arches will provide additional
insights into early myogenic specification of head muscle
precursor cells.
The functional consequences of delayed MyoD expres-
sion was a delay in muscle differentiation in branchialarches and limb buds, as assayed by Myogenin expression.
The delay in muscle differentiation, which is somewhat
more pronounced inMyoD knockout embryos (Kablar et al.,
1997), likely reflects the kinetics of accumulation of thresh-
old levels of MyoD and MRF4, which play compensatory
roles in muscle differentiation (Rawls et al., 1998). Whether
the delay in MyoD expression affected myoblast specifica-
tion in these lineages was not addressed, although no
obvious difference in early fetal musculature was observed.
In Myf-5 mutant embryos, a minority of presumptive myo-
genic cells incorporate into developing dermis and cartilage
of the trunk, while most undergo myogenesis (Tajbakhsh et
al., 1996). Presumably, the majority of presumptive muscle
precursors are rescued by MyoD, which is expressed later
than Myf-5 in myotomal muscles of wild-type embryos (Ott
et al., 1991; Sassoon et al., 1989), and is delayed further in
Myf-5 mutant embryos (Tajbakhsh et al., 1997); incorpora-
tion of some cells into non-muscle lineages may reflect a
myogenic subpopulation that does not express MyoD, or the
accumulation of only subthreshold levels of MyoD protein
during a critical developmental window. In this regard,
tracing the fates of presumptive muscle precursors in
core enhancer mutant embryos, as well as in CEloxP/loxP;
Myf-5/ embryos, a background in which all myogenesis is
MyoD-dependent (Rudnicki et al., 1993), will test whether
presumptive precursors remain competent to respond to
delayed myogenic stimulation and undergo muscle specifi-
cation upon initiation of MyoD expression.
Multiple enhancers regulate myotomal MyoD expression
The core enhancer was not required for MyoD expression
in nascent myocytes of the epaxial and hypaxial myotome or
in cell populations subjacent to the medial and lateral
dermomyotomal lips that may represent undifferentiated
precursors of the myotome referred to as the sub-lip domain
in birds (Cinnamon et al., 2001). This result was surprising,
as the core enhancer is the only known MyoD enhancer that
is sufficient to direct transgene expression in these somite
subpopulations, and deletion of a 4-kb fragment (fragment
3) that includes the core enhancer from a transgene con-
taining 24-kb of MyoD 5V flanking sequences abrogated
reporter gene expression in these regions through E11.5
(Chen et al., 2001). As all transgenic studies have been
conducted with the human core enhancer, it is formally
possible that species-specific core enhancer functions ex-
plain these differences, although the extensive sequence
similarity between the human and mouse enhancers (Gold-
hamer et al., 1995) argues against this possibility. It is also
possible that the DRR subserves compensatory functions
not part of its normal repertoire in core enhancer mutant
embryos, a notion that can be addressed in mice lacking
both enhancers. A more plausible explanation, however, is
the existence of at least one additional enhancer with
activity in these somite subdomains. This putative enhancer
could either reside outside of the 24-kb fragment used in
Fig. 5. A core enhancer domain required for myotomal and Pax-3-dependent transgene expression. (A, B, E, F) Comparison of human core enhancer transgene
activity (258/2.5lacZ) in wild-type andMyf-5 mutant embryos. Core enhancer activity was disrupted in somites ofMyf-5 mutant embryos at E11.5 (A, B), but
had largely recovered in myotomally derived musculature by E12.5 (E, F), closely phenocopying endogenous MyoD expression in a Myf-5 mutant background
(Chen et al., 2002; Tajbakhsh et al., 1997). (C, D, G, H) Linker-scanner 14 (not shown) and 15 (LS15/-2.5lacZ) mutations effectively eliminated transgene
expression in myotomes and their derivatives in wild-type embryos (C, G; Kucharczuk et al., 1999), and transgene expression was not rescued by Pax-3 inMyf-5
mutant embryos (D, H). Arrow, ectopic transgene expression due to integration effects.
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enhancer sequences of fragment 3, although the latter is less
likely as the majority of fragment 3 sequences have been
assayed in transgenic mice and found not to possess muscle-
specific activity (Goldhamer et al., 1995).
In Myf-5 mutant embryos, MyoD expression is delayed
by approximately 2 days in myotomes (Kablar et al., 1997;
Tajbakhsh et al., 1997), eventually recovering by a Pax-3-
dependent mechanism (Tajbakhsh et al., 1997). Previously,
we observed that adjacent linker-scanner mutations that
destroy a conserved E-box in the core enhancer result in a
transgene expression pattern reminiscent of MyoD expres-
sion in a Myf-5 null background, indicating that the core
enhancer may be a direct Myf-5 target (Kucharczuk et al.,
1999). Unlike expression of the endogenous MyoD gene,
however, myotomal expression of these mutant core en-
hancer transgenes does not recover, either in wild-type
embryos or, as shown here, in a Myf-5 mutant background,
indicating that Pax-3-dependent enhancer activity also
requires the enhancer domain defined by these linker-
scanner mutations. Nevertheless, in its normal chromosomal
context, the core enhancer is dispensable for Pax-3-depen-
dent MyoD expression in myotomal muscles, as recovery
of MyoD expression occurred with normal timing inCEloxP/loxP; Myf-5/ embryos. Furthermore, MyoD expres-
sion was detected in myotomes at E9.75 in both wild-type
and CEloxP/loxP embryos, showing that the core enhancer
also is not an essential cis target for Myf-5-dependent
MyoD expression. Interestingly, transgenic and knockout
studies have shown that the DRR is also dispensable for
Myf-5 regulation, and is sufficient but not necessary for
Pax-3-dependent expression. In this regard, the regulatory
relationship between the core enhancer and DRR will be
clarified in double enhancer knockout mice.
Concluding remarks
Although the spatial and temporal control of MyoD
expression can be recapitulated by the complementary
activities of the core enhancer and DRR (Chen et al.,
2001), analysis of core enhancer- and DRR-targeted mice
has revealed greater complexity of MyoD transcriptional
control mechanisms than anticipated from transgenic stud-
ies, demonstrating both unique and redundant activities for
each MyoD enhancer. Regulation of MyoD and Myf-5 share
as a common feature modular control by multiple enhancers
located at considerable distances from the genes they
regulate. This modularity is particularly pronounced for
Fig. 6. Deletion of the core enhancer did not affect Pax-3-dependent rescue of MyoD expression in Myf-5-mutant embryos. (A) Embryos heterozygous for both
CEloxP and Myf-5 exhibited normal MyoD expression throughout the mediolateral extent of the myotome at E11.5 (black arrows). (B, C) At E11.5, CE+/loxP;
Myf-5/ and CEloxP/loxP;Myf-5/ embryos showed weakMyoD expression in the ventrolateral myotomes of interlimb somites (black arrows), representing an
early phase of Pax-3-dependent compensation. MyoD expression in limb buds and branchial arch-derived myogenic cells of E11.5 embryos was unaffected by
the Myf-5 mutation, consistent with previous observations (Kablar et al., 1997; Tajbakhsh et al., 1997). (D–F) By E12.5, MyoD expression levels were normal
in myotomal muscles of Myf-5 mutant embryos both in the presence (E) and absence (F) of a functional core enhancer allele. Disorganization of trunk
musculature in Myf-5-mutant embryos (arrows) is the result of rib defects associated with the Myf-5m1 allele (Braun et al., 1992).
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the epaxial and hypaxial somite is controlled by several
distinct enhancers distributed up to 140 kb upstream of the
Myf-5 locus (Carvajal et al., 2001; Hadchouel et al., 2000;
Summerbell et al., 2000; Teboul et al., 2002; Zweigerdt et
al., 1997). Like MyoD, distinct ‘‘activation’’ and ‘‘mainte-
nance’’ enhancers have also been identified (Gustafsson et
al., 2002; Hadchouel et al., 2000; Teboul et al., 2002).
Targeting of the Myf-5 enhancers will establish the extent to
which these enhancers serve essential functions in their
normal chromosomal context, and their role, if any, in
controlling the expression of the closely linked muscle
regulatory gene, MRF4, which exhibits an overlapping
spatiotemporal pattern of expression.Acknowledgments
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